We are currently enrolling patients with idiopathic pulmonary fibrosis (IPF) in Phase 2 clinical trials for our lead investigational medicine, PLN-74809.
Here at Pliant, the world’s top experts in fibrosis biology are hard at work with experienced drug developers to find safe and effective therapies for people with idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and other fibrotic diseases.